Proteomic Studies Of β-amyloid (25-35)-treated PC12 Cells

Part I Neuroprotective effects of Rasagiline on PC12 cells treated by Aβ(25-35)Rasagiline is a selective MAO-B inhibitor produced by TEVA company. This new medicine has been used in clinical treatment of Parkinson disease. Now it is used in phase II of AD clinical trials. Studies have shown that it has neuroprotective effects, improves the activity of anti-oxidative enzymes in brain and reduces the neurotoxicity of ROS. Rasagiline can also inhibit AChE and antagonize apoptosis. Thus, it is a promising medicine in the treatment of AD.Objective To study the neuroprotective effects of Rasagiline on Aβ(25-35)-treated PC12 cells. Methods Part I: PC12 cells were treated with different concentrations of Aβ(25-35) (0.1, 1, 10, 20μM) for 48h, cell viability was measured by MTT conversion. Part II: PC12 cells were treated with different concentrations of Rasagiline (0.1μM, 1μM, 10μM) for 1h and then co-treated with 20μM Aβ(25-35) for 48 h. Cell viability was measured by MTT conversion and apoptotic rate was determined by fluorescent staining. Result 20μM Aβ(25-35) decreased the cell viability to 64%, 1μM Rasagiline significantly increased cell viability to 85%. The protective effects of Rasagiline on cell viability is significant (p<0.01). Treated with 20μM Aβ(25-35) for 48 h, the apoptotic rate of PC12 cells was 13%, co-treated with 1μM Rasagiline and...